Organisation paid for research Program year 2025 Source: CMS Open Payments

Walgreen Co

Neither a doctor nor a teaching hospital

Research payments

$590,448

38 payments

Through program year 2025, Walgreen Co is reported as receiving $590,448 in research payments, across 38 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$155,679	33
2024	Research	$429,280	4
2020	Research	$5,489	1

Breakdown

Who paid Research payments · program years 2020–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $584,959 37 payments
Ucb SA $5,489 1 payment

Studies the money was for Research payments · program years 2020–2025

phase III efficacy for obesity - with T2DM $348,280 3 payments
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus $155,679 33 payments
Phase III efficacy for obesity - without T2DM $81,000 1 payment
A Phase 3, Randomized, Doubl-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis $5,489 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.